Your session is about to expire
← Back to Search
Anti-fibrinolytic agent
Tranexamic Acid for Postinflammatory Hyperpigmentation
Phase 2 & 3
Waitlist Available
Led By Steven Daveluy
Research Sponsored by Wayne State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Summary
This trial is testing a skin cream called topical tranexamic acid to see if it can lighten dark spots from acne. It is aimed at people who can't use the usual treatment because of side effects. The cream works by reducing skin pigment and has few reported side effects.
Eligible Conditions
- Postinflammatory Hyperpigmentation
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Bile Pigments
Change from Baseline Pigmentation at 4 Weeks.
Change from Baseline Pigmentation at 8 Weeks.
Side effects data
From 2015 Phase 4 trial • 29 Patients • NCT020630358%
Postoperative wound infection
8%
Postoperative wound infection after release from hospital
8%
Myocardial infaction
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Tranexamic Acid
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Right Side of FaceExperimental Treatment1 Intervention
Patients will apply topical tranexamic acid to the dark spots on the one side of their face.
Group II: Left Side of FacePlacebo Group1 Intervention
Patients will apply the vehicle cream without any medication to the dark spots on one side of their face.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tranexamic Acid
2011
Completed Phase 4
~2740
Find a Location
Who is running the clinical trial?
Wayne State UniversityLead Sponsor
314 Previous Clinical Trials
110,078 Total Patients Enrolled
Steven DaveluyPrincipal InvestigatorWSUPG Dermatology
Share this study with friends
Copy Link
Messenger